Signal
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-acti...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-22 17:00 UTCUpdated 2026-01-22 18:00 UTC
rss
fierce_biotech
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic.
Fierce Biotech (All) · fiercebiotech.com · 2026-01-22 18:00 UTC
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-22 17:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)